Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112159 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NOD1ATMTSHRHPGD | |
| SCHEMBL112160 | 1.00 | ALDH1A1 (0.45) | ALDH1A1NOD1ATMTSHRHPGD | |
| SCHEMBL27723091 | 0.96 | NOD1 (0.45) | ALDH1A1NOD1ATMTSHRHPGD | |
| Sulfur Dioxide SCHEMBL27469685 | 0.95 | NOD1 (0.41) | ALDH1A1NOD1ATMTSHRHPGD | |
| SCHEMBL3260930 | 0.95 | NOD1 (0.49) | ALDH1A1NOD1TSHRHCAR2CYP3A4 | |
| SCHEMBL3260928 | 0.95 | NOD1 (0.49) | ALDH1A1NOD1TSHRHCAR2CYP3A4 | |
| SCHEMBL109771 | 0.93 | NOD1 (0.51) | ALDH1A1NOD1TSHRHCAR2LMNA | |
| SCHEMBL110954 | 0.93 | NOD1 (0.51) | ALDH1A1NOD1TSHRHCAR2LMNA | |
| SCHEMBL111688 | 0.93 | NOD1 (0.51) | ALDH1A1NOD1TSHRHCAR2LMNA | |
| SCHEMBL111261 | 0.93 | NOD1 (0.51) | ALDH1A1NOD1TSHRHCAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| CN-105820138-A | ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases | ABBVIE 公司 | 2016-08-03 | — | — | CN | disclosed |
| US-9339541-B2 | Thiophosphate nucleosides for the treatment of HCV | MERCK SHARP & DOHME CORP. (US) | 2016-05-17 | — | — | US | disclosed |
| CN-102655858-B | ABT-263 capsule | ABBVIE (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102802605-B | Stable lipid formulations of apoptosis promoters | ABBVIE (US) | 2015-08-12 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014137930-A1 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140248242-A1 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV | INDENIX PHARMACEUTICALS LLC | 2014-09-04 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| WO-2010147899-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBVIE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES | 2010-11-25 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010127190-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | BCL2L10, TMBIM6, BCOR | ALDH1A1 2745/4885NOD1 1503/4885ATM 3548/4885 |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCL2L2 | ALDH1A1 3413/4885NOD1 2124/4885ATM 2253/4885 |
| US-20140248242-A1 | THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV | PNP, MTAP, TYMP | ALDH1A1 789/4885NOD1 892/4885ATM 2010/4885 |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | BCL3, BCL2, BCL2L13 | ALDH1A1 4223/4885NOD1 2221/4885ATM 538/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | ALDH1A1 3985/4885NOD1 2795/4885ATM 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.